Jasna Jerecic, PhD, is an expert in technology transfer required for analytical development and validation for all CMC, toxicology and pharmacokinetic studies. Dr. Jerecic joined Acumen in 2003, where in collaboration with the Merck & Co. team, she developed neuronal screening assays that were critical to the identification and characterization of several highly efficacious anti-oligomer antibodies for Acumen’s drug discovery. She manages preclinical efficacy efforts and academic research collaborations for the advancement of ACU193. In addition, Dr Jerecic has successfully transferred and developed analytical assays for the characterization and quality control of monoclonal antibodies to industry partners. She received her PhD in molecular biology at the Max- Planck Institute for Medical Research and BA in biology and English from the University of Heidelberg in Germany.